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Abstract
Background: Recombinant human growth hormone (r-hGH) is used to treat: growth hormone
deficiency in children and adults; children born small for gestational age; Turner's syndrome; and
chronic renal failure. r-hGH is administered by daily subcutaneous injection and may be given using
a number of different administration devices. The aim of this survey was, firstly, to identify which
attributes of an r-hGH administration device are considered most important to physicians, teenage
patients, parents of young children requiring GH and nurses who have experience of r-hGH
administration, and, secondly, to determine how they rate existing devices in each of these key
attributes.
Methods: The opinions of 67 individuals with experience in r-hGH administration were captured
in discussion sessions. Parents, physicians and nurses were asked to rate 19 device attributes by
completing a questionnaire, and to rank four different r-hGH administration devices (including a
conceptual electronic device) in order of preference.
Results: Reliability, ease of use, lack of pain during injection, safety in use, storage, and number of
steps in preparation before use, during use and after were considered to be the five most desirable
attributes of an r-hGH administration device. An electronic device was preferred to an automatic,
multi-dose injection device, a needle-free injection device or a manual, ready-to-use, disposable
injection device.
Conclusion: In the opinion of physicians, nurses and parents using r-hGH injection devices, an
ideal device must combine reliability with simplicity, while delivering treatment with minimal pain.
An electronic device, which combines many of the most useful features of existing devices with
novel functions, was the preferred option for r-hGH administration.
Background
Approximately 1 in 4000 children are born every year with
growth hormone deficiency (GHD) [1]. GHD causes short
stature, low growth velocity, excess subcutaneous fat and
delayed skeletal maturation [1], which have a considera-
ble impact on physical and psychological functioning [2].
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Adults with untreated GHD also have an increased cardi-
ovascular risk [3]. Replacement therapy using exogenous
GH has been used successfully since the 1950s to treat
children (and more recently adults) with GHD [4,5].
Early preparations of GH were extracted from human
pituitary glands, but its use was discontinued in 1985 fol-
lowing the diagnosis of four cases of Creutzfeldt-Jakob
disease in patients who had received GH [6]. Later in the
same year, the first recombinant form of human GH (r-
hGH) became available. Initially, r-hGH was produced
using genetically engineered bacterial cells (Escherichia
coli) [7], but in 1987 a mammalian cell-derived r-hGH
preparation (produced by murine C127 cells) was intro-
duced [8]. With the advent of a new, unlimited source of
GH, researchers were able to explore the use of GH for
other conditions associated with growth retardation or
metabolic dysfunction. Today, GH is used to treat not
only GHD in both children and adults [4,5] but also a
number of other disorders, including Turner's syndrome
[9], chronic renal failure [10], and children born small for
gestational age [11].
To achieve optimal therapeutic results with GH, continu-
ous, long-term adherence is essential. However, all exist-
ing r-hGH products are administered subcutaneously,
usually on a daily basis, and this can lead to problems
with adherence [12]. Therefore, it is important that
devices used for r-hGH administration are convenient and
acceptable to patients. In particular, a large proportion of
the patients who require r-hGH therapy are children, so
an r-hGH administration device must be child-friendly.
The optimal device must be simple enough for a child to
operate easily and safely. The option of a hidden needle or
a needle-free device may also be particularly useful in
making the administration of r-hGH more acceptable to
children. The first commercially available preparations of
r-hGH were injected using a standard syringe, but novel
administration devices – pre-filled syringes, manual injec-
tor pens, auto-injectors, injectors with hidden needles and
needle-free devices – have since been introduced in an
attempt to increase dosing accuracy and adjustability, ease
of use, convenience, adherence, simplicity, and patient-
friendliness [13-21].
Despite these advances in r-hGH administration device
design, there is still scope for improvement. None of the
current devices are pain-free, and developments that
reduce pain or the patient's perception of pain (psycho-
logical pain) are also likely to increase adherence and
acceptance of therapy. In addition, it may be possible to
improve existing features or to introduce new, useful fea-
tures, such as pre-set dosing programmed by the physi-
cian, administration/cartridge replacement reminder
alarms or adjustable injection speeds. Some of these func-
tions may help to improve adherence but would need to
be incorporated in a way that did not compromise the
simplicity of the device.
The aim of this survey was, firstly, to identify which
attributes of an r-hGH injection device are considered
most important by physicians, teenage patients, parents
and nurses who have experience of GH administration,
and, secondly, to determine how these participants rate
existing devices in each of these key attributes, and to use
this to identify any unmet needs in GH injection devices.
Methods
Individuals were recruited for this survey in France, Ger-
many, Italy, the UK and the USA. Participants included
prescribing physicians (endocrinologists and paediatric
endocrinologists, no more than two from the same hospi-
tal, with recent experience of treating patients aged under
18 years with r-hGH), nurses involved in patient training
and support (community- or hospital-based, no more
than two from the same hospital), teenage patients (aged
between 13 and 15 years) self-injecting r-hGH using a
delivery device, and parents injecting their children (aged
under 14 years) with r-hGH. Recruitment of patients/par-
ents was facilitated with the assistance of medical profes-
sionals (in Europe) or patient associations (in the USA).
Group discussions involving three to six individuals were
conducted to assess opinions relating to r-hGH adminis-
tration device attributes. These discussions lasted 2–3
hours, were audio and video recorded, and were viewed
by up to five experts in a professional viewing room.
Where participants were unable to attend group discus-
sions (e.g. issues with geographical logistics), individual
face-to-face interviews were carried out (audio-recorded).
During these discussions and interviews, participants
were made aware of the current device options, asked to
brainstorm their desired alternative devices and to suggest
improvements.
Physicians, nurses and parents were also asked to com-
plete a questionnaire assessing which attributes they felt
to be the most important in a device for r-hGH adminis-
tration. The participants first spontaneously identified the
key device attributes that were important for them. These
attributes were then compared with a pre-existing list and
the participants were free to add extra attributes from this
list, if they wished. The participants were then asked to
score each of the selected attributes. A total of 19
attributes were assessed to evaluate the importance of
ergonomics, functionality and the psychological impact
of such a device: number of steps in preparation, no need
for reconstitution, ease of releasing trapped air, automatic
injecting, drug pre-loaded, disposable device, multi-dose,
ease of use, reliability, pain during injection, level of noiseBMC Endocrine Disorders 2006, 6:5 http://www.biomedcentral.com/1472-6823/6/5
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during injection, design aspects, position of release but-
ton, size, weight, level of physical strength required to
operate, ease of grip, ease of storage, safety in use and in
storage. Each attribute was rated from 0 (not important at
all) to 10 (extremely important). The questionnaire also
asked participants to rank the performance of existing r-
hGH injection devices that they had used previously for
each of these attributes, from 0 (not well at all) to 10
(extremely well). It was not considered appropriate for the
younger patients to complete a questionnaire, so only the
questionnaire results of parents, nurses and physicians are
presented below under Results. The children's views were
expressed spontaneously and key aspects were probed for
(e.g. their views on ease of use, size, etc.). These children
were also asked to produce drawings of desired features/
new devices during the group sessions.
Three r-hGH administration devices were demonstrated
during the discussion sessions: an automatic, multi-dose
injection device (one.click™, Serono, Geneva, Switzer-
land), a needle-free injection device (cool.click™, Serono,
Geneva, Switzerland) and a manual, ready-to-use, dispos-
able injection device (FlexPen®, Novo Nordisk, Dublin,
Ireland). The concept of an electronic device was also
introduced. Devices were ranked in order from 1 (pre-
ferred choice) to 4 (least preferred choice). In addition,
individual and consensus opinions relating to the
attributes of each device were captured during these dis-
cussions.
Mean scores were calculated for each attribute assessed in
the questionnaire. Mean scores were also calculated for
each attribute, grouped by participant type or by country.
Results
This survey assessed the views of 67 individuals: 19 endo-
crinologists (Germany, France, Italy and the USA), 18
nurses (UK, Germany, France and the USA), 12 patients
(UK and Germany) and 18 parents (Germany, France and
the USA). A total of 13 group discussions were conducted,
as well as seven face-to-face interviews (in France and the
USA).
Of the 19 key device attributes that were rated, partici-
pants considered the top five most important features of
an injection device to be:reliability, ease of use, lack of
pain during injection, safety in use and in storage, and the
number of steps in preparation before use, during use and
after (Figure 1). Parents, nurses and physicians all
regarded reliability as the most important device attribute
and ease of use as the second most important device
attribute. Participants in most countries (Germany, France
and the USA) considered reliability to be the most desira-
ble device attribute, while lack of pain during injection
and the number of steps in preparation were ranked the
most important device attributes by participants in the UK
and Italy, respectively.
Nearly all participants (58/67, 87%) had previous experi-
ence with the Genotropin Pen® (Pharmacia, Stockholm,
Sweden) and nearly half (32/67, 48%) had previous expe-
rience with the HumatroPen®  (Eli Lilly, Indianapolis,
USA) and/or the NordiPen® (30/67, 45%). Eight of the r-
hGH injection devices used previously by participants
were rated using the questionnaire. Mean scores for these
devices (grouped according to device type) in the five
attributes considered most desirable are shown in Figure
2.
Of the four device options that were demonstrated/intro-
duced during discussions, the electronic device was con-
sidered to be the preferred device option by parents (12/
17, 71%), physicians (11/13, 85%) and nurses (9/16,
56%; Figure 3). Of the remaining three devices, parents
generally preferred the cool.click™ needle-free device,
while physicians and nurses preferred the Flexpen® and/or
the one.click™ device.
Discussion
The nurses, physicians and parents questioned in this sur-
vey considered reliability to be the most important
attribute that they required from an r-hGH injection
Most important device attributes Figure 1
Most important device attributes. Mean scores for the 
five attributes of a recombinant human growth hormone 
administration device considered most important by partici-
pants in the survey. Device attributes (19 in total) were 
assessed in the questionnaire completed by physicians, 
nurses and parents.
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device. Device reliability encompasses not only the ability
of the device to deliver the injection of r-hGH each time it
is used, but also to confirm that the correct dose has been
administered. To ensure reliability, an r-hGH administra-
tion device must be robust enough to withstand daily use
and handling by young children. It is understandable that
reliability is considered to be so important to those using
r-hGH injection devices because, if a device stops func-
tioning, the patient/parent may need help to get it
repaired, and this must be done quickly to ensure conti-
nuity of treatment. Repairs may involve driving to the
pharmacy/hospital, which is both inconvenient and time-
consuming. For some devices, technical support is availa-
ble over the phone to help patients/parents rectify prob-
lems with their device at home.
Of the devices they had used previously, the participants
generally considered pre-filled syringes and auto-injector
pens to be highly reliable (mean score: 8.6–9.3). Only
four participants had previous experience with needle-free
devices and considered the reliability of these devices to
be relatively low (mean score: 2.0).
Participants considered 'ease of use' to be the second most
important attribute for an r-hGH injection device; ease of
use is particularly important when the device is being used
by a child or adolescent. A device with only a few steps in
preparation and for which dose adjustment/resetting is
straightforward will be simple to use. For children, the
size and weight of the device, as well as the strength
required to administer the injection will also be impor-
tant. Of the injection devices they had used previously,
participants found pre-filled syringes and auto-injector
pens very easy to use. The four patients who had previous
experience with needle-free devices considered them to be
moderately easy to use.
Lack of pain was considered by participants to be the third
most important attribute for an r-hGH injection device.
The pain and perceived pain associated with the adminis-
tration of a treatment may directly influence a patient's
adherence and acceptance of the therapy. Therefore, it is
important to minimise the pain and perceived pain asso-
ciated with the r-hGH injection process. A patient's expe-
rience of pain (both real and perceived) is related to both
injection technique and needle quality [22]. Of the
devices they had used previously, the participants associ-
ated all three types of r-hGH administration device with
similar levels of pain. These pain levels were rated as mod-
erate (mean score: 6–7) and, therefore, this highlights a
key area in which improvements could have a significant
positive impact on the patient. It may be possible to intro-
duce device design features that can reduce both the real
pain (e.g. finer needles and adjustable injection speeds)
and the perceived pain (e.g. needle-free or hidden-needle
options and noiseless operation) experienced by the
patient.
When asked to consider which type of device would best
meet their needs, parents, nurses and physicians in our
survey preferred the electronic device more than an auto-
matic, multi-dose injection device, a needle-free injection
device or a manual injection device. An electronic device
is also likely to be popular with children and teenagers
who are familiar with modern hand-held devices such as
mobile phones and computer games.
An electronic device has the potential to meet many of the
key patient needs highlighted by this survey. For example,
adherence aids (e.g. reminder messages and tracking func-
tions) could be incorporated, and these are particularly
desirable as they may help to increase the clinical effec-
tiveness of GH therapy. Multiple sensor and precision car-
tridge detection will provide reliable confirmation to the
patient or physician that the correct dose has been deliv-
ered. Pre-programmed dosing and automatic needle
attachment/detachment will both make the device easier
to use. Auto-injection using a permanent hidden needle
Comparative ratings for devices used previously Figure 2
Comparative ratings for devices used previously. 
Comparative ratings for recombinant human growth hor-
mone injection devices used previously by participants in the 
survey. Device attributes were assessed in the questionnaire 
completed by physicians, nurses and parents. Ratings are 
shown as mean scores for the five device attributes consid-
ered most desirable by survey participants.
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Preferences for devices demonstrated or introduced Figure 3
Preferences for devices demonstrated or introduced. Preferences expressed by parents (a), physicians (b) and nurses 
(c) for each of the four recombinant human growth hormone administration devices demonstrated (Flexpen®, cool.click™, 
one.click™) or introduced (electronic device) during discussion sessions. Devices were ranked in order from 1 (preferred 
choice) to 4 (least preferred choice). n/N refers to the number of individuals ranking each device out of the total number sur-
veyed. (a) – Preferences expressed by parents. (b) – Preferences expressed by physicians. (c) – Preferences expressed by 
nurses.
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will help to reduce the patient's perception of pain associ-
ated with the injection. In addition, such a device has the
potential to offer novel features such as adjustable injec-
tion speeds, noiseless operation, and a cartridge replace-
ment alarm.
Conclusion
Our survey indicates that, in the opinion of physicians,
nurses and parents using r-hGH injection devices, an ideal
future device must combine reliability with simplicity,
while delivering treatment with minimal pain. An elec-
tronic device was considered the preferred option for r-
hGH administration, compared with existing automatic
injection devices or prefilled syringes. An electronic device
combines many of the most useful features of existing r-
hGH administration devices with novel additional func-
tions, enabling it to meet the key needs of those who use
these devices.
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